dalteparin has been researched along with Injuries in 51 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Injuries: Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adult trauma patients receiving VTE chemoprophylaxis and hospitalized for at least 3 days were prospectively followed during two 6-month epochs before (PRE) and after (POST) implementation of anti-Xa monitoring." | 5.40 | Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. ( Athota, KP; Besl, KM; Droege, CA; Droege, ME; Ernst, NE; Hanseman, DJ; Keegan, SP; Kramer, EA; Lemmink, JA; Lutomski, DM; Mueller, EW; Robinson, BR, 2014) |
| " The purpose of this study was to compare the safety and efficacy of rivaroxaban to enoxaparin for the prevention of VTE in patients with multisystem injuries." | 3.91 | The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population. ( Kingdon, LK; Miller, EM; Savage, SA, 2019) |
| "1 IU/mL was considered subtherapeutic and the final dosage requirement was recorded." | 2.80 | Standard Dosing of Enoxaparin for Venous Thromboembolism Prophylaxis Is Not Sufficient for Most Patients Within a Trauma Intensive Care Unit. ( Ahmed, N; Allen, J; Brevard, SB; Frotan, AM; Gonzalez, RP; Replogle, WH; Rostas, JW; Simmons, JD; Thacker, D, 2015) |
| "To review the evidence regarding increased enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in the general trauma patient population." | 2.55 | Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients. ( Gales, MA; Horyna, TJ; Sandmann, EA; Walker, CK, 2017) |
| "Best practice in thromboprophylaxis for trauma patients will remain on the basis of recommendations until definitive risk-benefit ratios are determined to justify the use of various mechanical and pharmacological measures, in combination or alone." | 2.44 | Postinjury thromboprophylaxis. ( Balogh, Z; Bendinelli, C, 2008) |
| "Risk-adjusted Trauma Quality Improvement Program data showed an improvement in rate of symptomatic pulmonary embolism from fifth decile to first decile." | 1.72 | Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients. ( Collier, BR; Faulks, ER; Gates, RS; Gillen, JR; Lollar, DI; Smith, J, 2022) |
| "The use of initial weight-based enoxaparin dosing in trauma patients routinely achieved the prespecified target anti-Xa goal." | 1.62 | Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients. ( Huang, E; Martinez-Quinones, P; Robinson, T; Taylor, A; Waller, J; White, C, 2021) |
| " Standard prophylactic enoxaparin dosing was 40 mg SC daily, unless amended by the treating clinician." | 1.56 | The ATLANTIC study: Anti-Xa level assessment in trauma intensive care. ( Fitzgerald, M; Martin, EL; Rakhra, S; Udy, A, 2020) |
| "Orthopaedic trauma inpatients were included in the study." | 1.51 | Significant Reduction of Pulmonary Embolism in Orthopaedic Trauma Patients. ( Au, B; Cripps, MW; Eastman, A; Gebrelul, A; Hu, G; Minei, J; Sanders, D; Sathy, A; Shirley, Z; Starr, AJ; Sutphin, PD, 2019) |
| "Within 24 hours of admission, these trauma patients were screened with the Greenfield Risk Assessment Profile (RAP) (possible score range, 0-46)." | 1.48 | Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma. ( Dharmaraja, A; Eidelson, SA; Karcutskie, CA; Lama, G; Lineen, EB; Martin, AG; Namias, N; Padiadpu, AB; Patel, J; Proctor, KG; Schulman, CI, 2018) |
| "Accordingly, trauma services at the study institution endeavored to develop a standardized approach to optimize pharmacologic prevention with enoxaparin." | 1.48 | Improving Pharmacologic Prevention of VTE in Trauma: IMPACT-IT QI Project. ( Adams, E; Bethea, A; Chumbe, JT; Lucente, FC; Samanta, D, 2018) |
| "A retrospective analysis of trauma patients from July 2016 to June 2017 who received enoxaparin 40 mg twice daily and had peak Xa levels drawn was performed." | 1.48 | Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin. ( Clark, AT; Cripps, MW; Cunningham, HB; Eastman, AL; Huang, E; Imran, JB; Kacir, CD; Koshy, JP; Madni, TD; Minshall, CT; Rizk, P; Taveras, LR, 2018) |
| " Furthermore, these levels were never achieved in some trauma patients despite repeated dosing over a >10-day period." | 1.46 | Relation of antifactor-Xa peak levels and venous thromboembolism after trauma. ( Dharmaraja, A; Eidelson, SA; Karcutskie, CA; Lineen, EB; Martin, AG; Namias, N; Patel, J; Proctor, KG; Schulman, CI, 2017) |
| " Goal anti-Xa levels were met initially in only 46% of patients despite dosing of >40mg twice daily in 81% of patients; however, with titration, goal anti-Xa levels were achieved in an additional 109 patients (36%)." | 1.46 | Goal directed enoxaparin dosing provides superior chemoprophylaxis against deep vein thrombosis. ( Basharat, U; Bogert, JN; Davis, KM; Kopelman, TR; Pieri, PG; Pressman, MA; Quan, AN; Vail, SJ; Walters, JW, 2017) |
| "Records of 318 trauma patients were evaluated, and NONMEM and PSN software were used to analyze 11 variables for their effects on anti-Xa levels." | 1.43 | If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis. ( Berndtson, AE; Box, K; Coimbra, R; Costantini, TW; Lane, J, 2016) |
| "Sex effects on VTE after trauma are unclear." | 1.43 | Does sex matter? Effects on venous thromboembolism risk in screened trauma patients. ( Berndtson, AE; Coimbra, R; Costantini, TW; Kobayashi, L; Smith, AM, 2016) |
| " Enoxaparin dosage adjustment may lead to a reduced rate of VTE without an increased risk of bleeding." | 1.43 | Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. ( Barmparas, G; Chung, K; Dhillon, N; Gewertz, BL; Harada, MY; Ko, A; Ley, EJ; Margulies, DR; Mason, R; Yim, DA, 2016) |
| " Dosage was adjusted to a prophylactic peak anti-Xa level of 0." | 1.43 | Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients. ( Ginzburg, E; Karcutskie, CA; Lieberman, HM; Lineen, EB; Namias, N; Riggi, G; Singer, GA; Vaghaiwalla, TM, 2016) |
| "The median time from trauma to filter insertion was 2days and low molecular weight heparin at prophylactic dose was initiated in 92% once the filter was inserted." | 1.42 | The use of optional inferior vena cava filters of type Optease in trauma patients--a single type of filter in a single Medical Center. ( Grossman, E; Khaitovich, B; Kleinbaum, Y; Lavan, O; Rimon, U; Salomon, O; Segal, B; Simon, D; Steinberg, DM, 2015) |
| "The Michigan Trauma Quality Improvement Program (MTQIP) is a collaborative quality initiative sponsored by Blue Cross Blue Shield of Michigan and Blue Care Network (BCBSM/BCN)." | 1.42 | Reduction in Venous Thromboembolism Events: Trauma Performance Improvement and Loop Closure Through Participation in a State-Wide Quality Collaborative. ( Cherry-Bukowiec, JR; Hemmila, MR; Jakubus, JL; Machado-Aranda, DA; Napolitano, LM; Park, PK; Raghavendran, K; To, KB; Wahl, WL, 2015) |
| " The DVT rate did not differ between trauma and general surgery populations or in patients receiving once-daily vs twice-daily dosing regimens." | 1.40 | Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients. ( Anderson, R; Barton, JS; Cho, SD; Differding, J; Geraci, T; Louis, SG; Riha, GM; Sato, M; Schreiber, MA; Underwood, S; Van, PY; Watters, JM, 2014) |
| "Adult trauma patients receiving VTE chemoprophylaxis and hospitalized for at least 3 days were prospectively followed during two 6-month epochs before (PRE) and after (POST) implementation of anti-Xa monitoring." | 1.40 | Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. ( Athota, KP; Besl, KM; Droege, CA; Droege, ME; Ernst, NE; Hanseman, DJ; Keegan, SP; Kramer, EA; Lemmink, JA; Lutomski, DM; Mueller, EW; Robinson, BR, 2014) |
| "In obese trauma patients, weight-based enoxaparin is an efficacious regimen that provides adequate VTE prophylaxis, as measured by anti-Xa levels, and appears to be safe without bleeding complications." | 1.39 | Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. ( Bickford, A; Bledsoe, J; Dickerson, J; Johnston, R; Majercik, S; Smith, K; White, T, 2013) |
| "A retrospective review was performed of trauma patients who received prophylactic enoxaparin and peak anti-Xa levels over 27 months." | 1.39 | Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer? ( Hall, ST; Kopelman, TR; O'Neill, PJ; Pieri, PG; Pressman, MS; Quan, A; Salomone, JP; Wells, JR, 2013) |
| "Sixty-one trauma patients met inclusion criteria." | 1.39 | Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. ( Bansal, V; Box, K; Coimbra, R; Costantini, TW; Doucet, J; Fortlage, D; Min, E; Tran, V; Winfield, RD, 2013) |
| "All high-risk trauma patients were evaluated with weekly duplex Doppler ultrasonography." | 1.39 | The effects of location and low-molecular-weight heparin administration on deep vein thrombosis outcomes in trauma patients. ( Alonzo, BJ; Differding, J; Hamilton, G; Kremenevskiy, I; Lee, TH; McNamara, S; Schreiber, MA; Underwood, SJ, 2013) |
| "Venous thromboembolism was significantly associated with pelvic fractures, intensive care unit stay, and central venous catheters (P = ." | 1.38 | Increased use of enoxaparin in pediatric trauma patients. ( Askegard-Giesmann, JR; Kenney, BD; O'Brien, SH; Wang, W, 2012) |
| "Eighty-five percent suffered trauma (Injury Severity Score of 25 +/- 12) and 74% were male." | 1.36 | Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. ( Ardary, C; Baje, M; Barrios, C; Cinat, ME; Conniff, H; Dolich, MO; Ewing, T; Hoyt, DB; Jafari, F; Kong, A; Lekawa, ME; Malinoski, D, 2010) |
| " Multiple drugs and dosing regimens have been suggested for pharmacoprophylaxis." | 1.36 | Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients. ( Arnold, JD; Barker, DE; Burkholder, HC; Dart, BW; Longley, JM; Maxwell, RA; Mejia, VA; Smith, PW, 2010) |
| "Trauma patients at a Level I Trauma Center found to be nonambulatory or otherwise high risk were placed on a protocol of lower-extremity (LE) compression devices and subcutaneous enoxaparin as soon as feasible after admission." | 1.35 | Four years of an aggressive prophylaxis and screening protocol for venous thromboembolism in a large trauma population. ( Adams, RC; Berenguer, C; Hamrick, M; Ochsner, MG; Senkowski, C, 2008) |
| "In 234 trauma surgery patients, thrombosis prophylaxis with Nadroparin-Calcium low-molecular-weight heparin (LMWH) was adjusted according to levels of D-Dimer." | 1.31 | Dose-adjusted thrombosis prophylaxis in trauma surgery according to levels of D-Dimer. ( Hafner, G; Hansen, M; Mayer, A; Peetz, D; Prellwitz, W; Rippin, G; Rommens, PM, 2000) |
| "Most injuries were related to motor vehicles (52%) and falls (30%)." | 1.31 | Implementation and evaluation of guidelines for use of enoxaparin as deep vein thrombosis prophylaxis after major trauma. ( Devlin, JW; Moed, B; Tyburski, JG, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.96) | 18.2507 |
| 2000's | 11 (21.57) | 29.6817 |
| 2010's | 31 (60.78) | 24.3611 |
| 2020's | 8 (15.69) | 2.80 |
| Authors | Studies |
|---|---|
| Haentjens, P | 1 |
| Peetz, D | 1 |
| Hafner, G | 1 |
| Hansen, M | 1 |
| Mayer, A | 1 |
| Rippin, G | 1 |
| Rommens, PM | 1 |
| Prellwitz, W | 1 |
| Gates, RS | 1 |
| Lollar, DI | 1 |
| Collier, BR | 1 |
| Smith, J | 1 |
| Faulks, ER | 1 |
| Gillen, JR | 1 |
| Schroeppel, TJ | 1 |
| Clement, LP | 1 |
| Douville, AA | 1 |
| Schmoekel, NH | 1 |
| Stassinopoulos, J | 1 |
| Decker, C | 1 |
| Stillman, ZE | 1 |
| Rodriquez, J | 1 |
| Brockman, VP | 1 |
| Hennessy, E | 1 |
| Heise, H | 1 |
| Khan, AD | 1 |
| Borst, JM | 1 |
| Modi, RN | 1 |
| Kirchberg, TN | 1 |
| Box, K | 3 |
| Smith, AM | 2 |
| Godat, LN | 1 |
| Doucet, JJ | 1 |
| Costantini, TW | 4 |
| Berndtson, AE | 3 |
| Rakhra, S | 1 |
| Martin, EL | 1 |
| Fitzgerald, M | 1 |
| Udy, A | 1 |
| Çevirme, D | 1 |
| Savluk, ÖF | 1 |
| Başaran, EK | 1 |
| Aksoy, R | 1 |
| Elibol, A | 1 |
| Baş, T | 1 |
| Keser, S | 1 |
| Adademir, T | 1 |
| Yılmaz, B | 1 |
| Krantz, EN | 1 |
| Philpott, CD | 2 |
| Droege, ME | 3 |
| Mueller, EW | 3 |
| Ernst, NE | 3 |
| Garber, PM | 1 |
| Tsuei, BJ | 1 |
| Goodman, MD | 1 |
| Droege, CA | 3 |
| Farrar, JE | 1 |
| Makley, AT | 2 |
| Deichstetter, KM | 1 |
| Taylor, A | 1 |
| Huang, E | 2 |
| Waller, J | 1 |
| White, C | 1 |
| Martinez-Quinones, P | 1 |
| Robinson, T | 1 |
| Miano, TA | 1 |
| Cuker, A | 1 |
| Christie, JD | 1 |
| Martin, N | 1 |
| Smith, B | 1 |
| Guo, W | 1 |
| Hennessy, S | 1 |
| Karcutskie, CA | 3 |
| Dharmaraja, A | 2 |
| Patel, J | 2 |
| Eidelson, SA | 2 |
| Padiadpu, AB | 1 |
| Martin, AG | 2 |
| Lama, G | 1 |
| Lineen, EB | 3 |
| Namias, N | 3 |
| Schulman, CI | 2 |
| Proctor, KG | 2 |
| Bethea, A | 1 |
| Adams, E | 1 |
| Lucente, FC | 1 |
| Samanta, D | 1 |
| Chumbe, JT | 1 |
| Imran, JB | 1 |
| Madni, TD | 1 |
| Clark, AT | 1 |
| Rizk, P | 1 |
| Minshall, CT | 1 |
| Taveras, LR | 1 |
| Cunningham, HB | 1 |
| Eastman, AL | 1 |
| Koshy, JP | 1 |
| Kacir, CD | 1 |
| Cripps, MW | 2 |
| Starr, AJ | 1 |
| Shirley, Z | 1 |
| Sutphin, PD | 1 |
| Sanders, D | 1 |
| Eastman, A | 1 |
| Au, B | 1 |
| Sathy, A | 1 |
| Hu, G | 1 |
| Gebrelul, A | 1 |
| Minei, J | 1 |
| Kingdon, LK | 1 |
| Miller, EM | 1 |
| Savage, SA | 1 |
| Bickford, A | 1 |
| Majercik, S | 1 |
| Bledsoe, J | 1 |
| Smith, K | 1 |
| Johnston, R | 1 |
| Dickerson, J | 1 |
| White, T | 1 |
| Kopelman, TR | 2 |
| O'Neill, PJ | 1 |
| Pieri, PG | 2 |
| Salomone, JP | 1 |
| Hall, ST | 1 |
| Quan, A | 1 |
| Wells, JR | 1 |
| Pressman, MS | 1 |
| Bandle, J | 2 |
| Shackford, SR | 2 |
| Sise, CB | 2 |
| Knudson, MM | 1 |
| Gritsiouk, Y | 1 |
| Hegsted, DA | 1 |
| Schlesinger, P | 1 |
| Gardiner, SK | 1 |
| Gubler, KD | 1 |
| Galante, JM | 1 |
| Louis, SG | 1 |
| Sato, M | 1 |
| Geraci, T | 1 |
| Anderson, R | 1 |
| Cho, SD | 1 |
| Van, PY | 1 |
| Barton, JS | 1 |
| Riha, GM | 1 |
| Underwood, S | 1 |
| Differding, J | 2 |
| Watters, JM | 1 |
| Schreiber, MA | 2 |
| Lavan, O | 1 |
| Rimon, U | 1 |
| Simon, D | 1 |
| Khaitovich, B | 1 |
| Segal, B | 1 |
| Grossman, E | 1 |
| Kleinbaum, Y | 1 |
| Steinberg, DM | 1 |
| Salomon, O | 1 |
| Machado-Aranda, DA | 1 |
| Jakubus, JL | 1 |
| Wahl, WL | 1 |
| Cherry-Bukowiec, JR | 1 |
| To, KB | 1 |
| Park, PK | 1 |
| Raghavendran, K | 1 |
| Napolitano, LM | 1 |
| Hemmila, MR | 1 |
| Olson, EJ | 1 |
| Calvo, RY | 1 |
| Dunne, CE | 1 |
| Van Gent, JM | 1 |
| Zander, AL | 1 |
| Sikand, H | 1 |
| Bongiovanni, MS | 1 |
| Sise, MJ | 1 |
| Rostas, JW | 1 |
| Brevard, SB | 1 |
| Ahmed, N | 1 |
| Allen, J | 1 |
| Thacker, D | 1 |
| Replogle, WH | 1 |
| Gonzalez, RP | 1 |
| Frotan, AM | 1 |
| Simmons, JD | 1 |
| Lane, J | 1 |
| Coimbra, R | 3 |
| Kobayashi, L | 1 |
| Ko, A | 1 |
| Harada, MY | 1 |
| Barmparas, G | 1 |
| Chung, K | 1 |
| Mason, R | 1 |
| Yim, DA | 1 |
| Dhillon, N | 1 |
| Margulies, DR | 1 |
| Gewertz, BL | 1 |
| Ley, EJ | 1 |
| Singer, GA | 1 |
| Riggi, G | 1 |
| Vaghaiwalla, TM | 1 |
| Lieberman, HM | 1 |
| Ginzburg, E | 1 |
| Coleman, J | 1 |
| Baldawi, M | 1 |
| Heidt, D | 1 |
| Walters, JW | 1 |
| Bogert, JN | 1 |
| Basharat, U | 1 |
| Davis, KM | 1 |
| Quan, AN | 1 |
| Vail, SJ | 1 |
| Pressman, MA | 1 |
| Walker, CK | 1 |
| Sandmann, EA | 1 |
| Horyna, TJ | 1 |
| Gales, MA | 1 |
| Adams, RC | 1 |
| Hamrick, M | 1 |
| Berenguer, C | 1 |
| Senkowski, C | 1 |
| Ochsner, MG | 1 |
| Bendinelli, C | 1 |
| Balogh, Z | 1 |
| Malinoski, D | 1 |
| Jafari, F | 1 |
| Ewing, T | 1 |
| Ardary, C | 1 |
| Conniff, H | 1 |
| Baje, M | 1 |
| Kong, A | 1 |
| Lekawa, ME | 1 |
| Dolich, MO | 1 |
| Cinat, ME | 1 |
| Barrios, C | 1 |
| Hoyt, DB | 1 |
| Arnold, JD | 1 |
| Dart, BW | 1 |
| Barker, DE | 1 |
| Maxwell, RA | 1 |
| Burkholder, HC | 1 |
| Mejia, VA | 1 |
| Smith, PW | 1 |
| Longley, JM | 1 |
| Tsiridis, E | 1 |
| Gamie, Z | 1 |
| George, MJ | 1 |
| Hamilton-Baille, D | 1 |
| West, RM | 1 |
| Giannoudis, PV | 1 |
| Askegard-Giesmann, JR | 1 |
| O'Brien, SH | 1 |
| Wang, W | 1 |
| Kenney, BD | 1 |
| Min, E | 1 |
| Tran, V | 1 |
| Winfield, RD | 1 |
| Fortlage, D | 1 |
| Doucet, J | 1 |
| Bansal, V | 1 |
| Lee, TH | 1 |
| Alonzo, BJ | 1 |
| Underwood, SJ | 1 |
| Hamilton, G | 1 |
| Kremenevskiy, I | 1 |
| McNamara, S | 1 |
| Buckenmaier, CC | 2 |
| Shields, CH | 1 |
| Auton, AA | 1 |
| Evans, SL | 1 |
| Croll, SM | 1 |
| Bleckner, LL | 2 |
| Brown, DS | 1 |
| Stojadinovic, A | 1 |
| Lynd, LD | 2 |
| Goeree, R | 2 |
| Crowther, MA | 2 |
| O'Brien, BJ | 2 |
| Landi, F | 1 |
| Bernabei, R | 1 |
| Trecca, A | 1 |
| Marzi, D | 1 |
| Russo, A | 1 |
| Carosella, L | 1 |
| Cocchi, A | 1 |
| Devlin, JW | 1 |
| Tyburski, JG | 1 |
| Moed, B | 1 |
| Shorr, AF | 1 |
| Ramage, AS | 1 |
| Selby, R | 1 |
| Geerts, WH | 1 |
| Besl, KM | 1 |
| Lemmink, JA | 1 |
| Kramer, EA | 1 |
| Athota, KP | 1 |
| Keegan, SP | 1 |
| Lutomski, DM | 1 |
| Hanseman, DJ | 1 |
| Robinson, BR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265] | Phase 3 | 329 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Norwegian Intensive Care Unit Dalteparin Effect Study[NCT01721928] | 70 participants (Actual) | Observational | 2012-12-03 | Completed | |||
| Comparative Feasibility and Efficacy of a Five Compartment Technique Using 0.25% Bupivacaine vs a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka; a Single Blinded Randomized Controlled Study[NCT03303794] | Phase 3 | 25 participants (Actual) | Interventional | 2017-10-25 | Terminated (stopped due to Interim Analysis showed no significance) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 5 |
| VTE Prophylaxis With Aspirin 81mg BID | 9 |
Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 6 |
| VTE Prophylaxis With Aspirin 81mg BID | 2 |
Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 52 |
| VTE Prophylaxis With Aspirin 81mg BID | 53 |
AM-PAC (activity measure for post-acute care) will be used to determine if a patient is fit to discharge based on mobility with 6 being unable to mobilize up to 24 being independent. Patients who scored above 20 were considered fit to discharge. (NCT03303794)
Timeframe: Post-Operation Day 1
| Intervention | score on scale (Mean) |
|---|---|
| Bupivicaine | 23 |
| Bupivicaine + Exparel | 23 |
Monitor how much opioid patient consumes (NCT03303794)
Timeframe: During the first 48 hours after surgery
| Intervention | milligram (Mean) |
|---|---|
| Bupivicaine | 90 |
| Bupivicaine + Exparel | 76 |
Will use Numeric Pain Rating Scale (NPRS) to measure pain with 0 being no pain and 10 being the worst pain. (NCT03303794)
Timeframe: 48 hours postoperatively
| Intervention | score on scale (Mean) |
|---|---|
| Bupivicaine | 4 |
| Bupivicaine + Exparel | 4 |
3 reviews available for dalteparin and Injuries
| Article | Year |
|---|---|
Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
Topics: Anticoagulants; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxapa | 2017 |
Postinjury thromboprophylaxis.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Factor Xa Inhibitors; Fondaparinux; Humans; Incidence; | 2008 |
Early postoperative bleeding in polytrauma patients treated with fondaparinux: literature review and institutional experience.
Topics: Acetabulum; Adult; Anticoagulants; Enoxaparin; Female; Fondaparinux; Fractures, Bone; Humans; Male; | 2011 |
4 trials available for dalteparin and Injuries
| Article | Year |
|---|---|
Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium)
Topics: Aged; Anticoagulants; Drug Administration Schedule; Female; Hip Fractures; Humans; Leg Injuries; Mal | 1996 |
Heparin versus enoxaparin for prevention of venous thromboembolism after trauma: A randomized noninferiority trial.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Intensive Care Units; Male; Middle Aged; | 2015 |
Standard Dosing of Enoxaparin for Venous Thromboembolism Prophylaxis Is Not Sufficient for Most Patients Within a Trauma Intensive Care Unit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Mass Index; Dose-Response Relations | 2015 |
Early postoperative bleeding in polytrauma patients treated with fondaparinux: literature review and institutional experience.
Topics: Acetabulum; Adult; Anticoagulants; Enoxaparin; Female; Fondaparinux; Fractures, Bone; Humans; Male; | 2011 |
45 other studies available for dalteparin and Injuries
| Article | Year |
|---|---|
Dose-adjusted thrombosis prophylaxis in trauma surgery according to levels of D-Dimer.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Antithrombin III; Biomarkers; Female; Fibri | 2000 |
Enoxaparin titrated by anti-Xa levels reduces venous thromboembolism in trauma patients.
Topics: Blood Coagulation Tests; Chemoprevention; Dose-Response Relationship, Drug; Drug Dosage Calculations | 2022 |
Time is of the Essence: Impact of a More Aggressive Chemical Venous Thromboembolism Prophylaxis Regimen on Trauma Patients.
Topics: Adult; Aged; Algorithms; Anticoagulants; Blood Transfusion; Colorado; Enoxaparin; Female; Humans; In | 2022 |
You're never too old for optimal venous thromboembolism prophylaxis: Re-thinking current trauma guidelines.
Topics: Anticoagulants; Enoxaparin; Humans; Venous Thromboembolism; Wounds and Injuries | 2022 |
The ATLANTIC study: Anti-Xa level assessment in trauma intensive care.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Injections, Subcutaneous; Intensive Care Un | 2020 |
Effects of anticoagulant drugs on wound healing process in a rat model: a comparative study.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Anticoagulants; Dabigatran; Enoxaparin; Fe | 2020 |
Retrospective Evaluation of Venous Thromboembolism Prophylaxis in Elderly, High-Risk Trauma Patients.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Anticoagulants; Enoxaparin; Female; Humans; Incidence; | 2020 |
Impact of Weight on Anti-Xa Attainment in High-Risk Trauma Patients on Enoxaparin Chemoprophylaxis.
Topics: Adult; Age Factors; Aged; Body Weight; Dose-Response Relationship, Drug; Drug Dosage Calculations; E | 2021 |
Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Goals; Hemorrhage; Heparin, Low-Molecular-W | 2021 |
Comparative Effectiveness of Enoxaparin vs Dalteparin for Thromboprophylaxis After Traumatic Injury.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Comparative Effectiveness Research; Dalteparin; Drug | 2018 |
Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Topics: Adult; Aged; Anticoagulants; Computed Tomography Angiography; Enoxaparin; Factor Xa Inhibitors; Fema | 2018 |
Relation of antifactor-Xa peak levels and venous thromboembolism after trauma.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Embolic Protection Devices; Enoxaparin; Factor | 2017 |
Improving Pharmacologic Prevention of VTE in Trauma: IMPACT-IT QI Project.
Topics: Adult; Aged; Anticoagulants; Cohort Studies; Enoxaparin; Factor Xa; Female; Humans; Male; Middle Age | 2018 |
Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Hemorrhage; Humans; Information Storage and Re | 2018 |
Significant Reduction of Pulmonary Embolism in Orthopaedic Trauma Patients.
Topics: Adult; Aged; Anticoagulants; Clinical Protocols; Enoxaparin; Female; Humans; Incidence; Male; Middle | 2019 |
The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population.
Topics: Adult; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Length of Stay; Male; Middle Aged; Retrospe | 2019 |
Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient.
Topics: Anticoagulants; Body Mass Index; Dose-Response Relationship, Drug; Enoxaparin; Female; Follow-Up Stu | 2013 |
Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?
Topics: Adult; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; Factor Xa Inhibitors | 2013 |
Variability is the standard: the management of venous thromboembolic disease following trauma.
Topics: Anticoagulants; Data Collection; Enoxaparin; Humans; Practice Patterns, Physicians'; United States; | 2014 |
A retrospective analysis of the effectiveness of low molecular weight heparin for venous thromboembolism prophylaxis in trauma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Enoxaparin; Female; Huma | 2014 |
Order and execution of DVT prophylaxis: "the best-laid plans of mice and men".
Topics: Enoxaparin; Female; Humans; Male; Surgical Procedures, Operative; Trauma Centers; Venous Thrombosis; | 2014 |
Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Follow-Up Studies; Humans; Inc | 2014 |
The use of optional inferior vena cava filters of type Optease in trauma patients--a single type of filter in a single Medical Center.
Topics: Adolescent; Adult; Anticoagulants; Contraindications; Device Removal; Embolism; Enoxaparin; Equipmen | 2015 |
Reduction in Venous Thromboembolism Events: Trauma Performance Improvement and Loop Closure Through Participation in a State-Wide Quality Collaborative.
Topics: Anticoagulants; Clinical Protocols; Enoxaparin; Heparin; Humans; Injury Severity Score; Michigan; Qu | 2015 |
If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis.
Topics: Adult; Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxapa | 2016 |
Does sex matter? Effects on venous thromboembolism risk in screened trauma patients.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Hospitalization; Humans; Male; Middle Aged; Registries; R | 2016 |
Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Topics: Adult; Anticoagulants; Enoxaparin; Erythrocyte Transfusion; Factor Xa Inhibitors; Female; Hematocrit | 2016 |
Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients.
Topics: Abbreviated Injury Scale; Adult; Aged; Anticoagulants; Enoxaparin; Factor Xa; Female; Humans; Male; | 2016 |
The effect anticoagulation status on geriatric fall trauma patients.
Topics: Accidental Falls; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Critical Care; | 2016 |
Goal directed enoxaparin dosing provides superior chemoprophylaxis against deep vein thrombosis.
Topics: Abbreviated Injury Scale; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Chemopreventio | 2017 |
Four years of an aggressive prophylaxis and screening protocol for venous thromboembolism in a large trauma population.
Topics: Adult; Anticoagulants; Clinical Protocols; Enoxaparin; Female; Humans; Incidence; Intermittent Pneum | 2008 |
Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Humans; Injury Severity Score; Male; Prospecti | 2010 |
Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Cost Savings; Enoxaparin; Female; Head I | 2010 |
Increased use of enoxaparin in pediatric trauma patients.
Topics: Adolescent; Child; Child, Preschool; Databases, Factual; Drug Utilization; Enoxaparin; Fibrinolytic | 2012 |
Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male | 2013 |
The effects of location and low-molecular-weight heparin administration on deep vein thrombosis outcomes in trauma patients.
Topics: Adult; Aged; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Injury | 2013 |
Continuous peripheral nerve block in combat casualties receiving low-molecular weight heparin.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Humans; Iraq; Male; Middle | 2006 |
Continuous peripheral nerve catheters in patients receiving low molecular weight heparin.
Topics: Anticoagulants; Catheters, Indwelling; Device Removal; Drug Administration Schedule; Enoxaparin; Fem | 2007 |
A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Topics: Adult; Anticoagulants; Bayes Theorem; Canada; Cost-Benefit Analysis; Decision Support Techniques; De | 2007 |
A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Topics: Adult; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Trees; Enoxaparin; Female; Heparin; | 2007 |
Physical restraint and subcutaneous hematoma in an anticoagulated patient.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Hematoma; Humans; Male; Restraint, Physical; Ri | 2001 |
Implementation and evaluation of guidelines for use of enoxaparin as deep vein thrombosis prophylaxis after major trauma.
Topics: Adult; Enoxaparin; Female; Guidelines as Topic; Humans; Male; Middle Aged; Venous Thrombosis; Wounds | 2001 |
Enoxaparin for thromboprophylaxis after major trauma: potential cost implications.
Topics: Anticoagulants; Cost-Benefit Analysis; Decision Making; Enoxaparin; Heparin, Low-Molecular-Weight; H | 2001 |
Venous thromboembolism prophylaxis after trauma: dollars and sense.
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Venous Thrombosis; Wounds and Inj | 2001 |
Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
Topics: Adult; Aged; Anticoagulants; Cohort Studies; Dalteparin; Dose-Response Relationship, Drug; Drug Admi | 2014 |